|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C12N 9/18 | |
| A61K 38/46 | |||
| A61K 31/135 | |||
| A61K 31/366 | |||
| A61K 31/397 | |||
| A61K 31/465 | |||
| A61P 3/06 |
| (11) | Patento numeris | 2977057 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 14200334.2 |
| Europos patento paraiškos padavimo data | 2011-09-09 | |
| (97) | Europos patento paraiškos paskelbimo data | 2016-01-27 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-11-06 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 403011 P | 2010-09-09 | US | |
| 456014 P | 2010-10-29 | US | |
| 201161432372 P | 2011-01-13 | US | |
| PCT/US2011/0336 | 2011-04-23 | WO |
| (72) |
Quinn, Anthony, US
|
| (73) |
Alexion Pharmaceuticals, Inc.,
121 Seaport Boulevard, Boston, MA 02210,
US
|
| (54) | ISOLATED RECOMBINANT HUMAN N-GLYCOSYLATED LYSOSOMAL ACID LIPASE |
| ISOLATED RECOMBINANT HUMAN N-GLYCOSYLATED LYSOSOMAL ACID LIPASE |